Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uninterrupted DOAC in Transradial Coronary Procedures
NCT05292846Phase 4Recruiting
- Sponsor
- Hospital Universitari i Politècnic La Fe
- Start
- Jan 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 4 trial of apixaban, dabigatran etexilate oral solution, edoxaban, rivaroxaban in coronary artery disease (CAD), sponsored by Hospital Universitari i Politècnic La Fe. Started Jan 2022; status: recruiting.
02
Drugs
apixabandabigatran etexilate oral solutionedoxabanrivaroxaban
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05292846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05292846.